Citations

Clear

400 citation(s) found for "Sm, Berry".

Abstract P3-07-49: Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial
Liu, MC, Symmans, WF, Rugo, HS, Olopade, OF, Datnow, Brian, Hasteh, Farnaz, Tickman, Ronald, Troxel, Mary , Mhawech‐Fauceglia, Paulette , Duan, Xiuzhen, Berry, D. A., Yau, Christina , Chen, Yung‐Yi , Chen, Bin , Feldman, Michael D. , Kallakury, Bhaskar , Ritter, Jacob , Esserman, Laura J. , DeMichele, Angela

Mayo Clinic

Cancer Research | May 20, 2016 | Volume: 76 | Issue: 4_Supplement | Pages: P3-07-49-P3-07-49

10.1158/1538-7445.sabcs15-p3-07-49 Get It

Abstract Background: I-SPY2 is a multicenter phase 2 trial in high risk stage II/III breast cancer (BC) using adaptive randomization within biomarker subtypes to evaluate novel agents added to standard neoadjuvant chemotherapy. The first regimen to graduate based on the predicted probability of a higher pCR rate within predefined subsets was veliparib/carboplatin + paclitaxel (VC+T→AC vs T→AC) in triple negative BC (TNBC). In TNBC the residual cancer burden (RCB) is prognostic, whether as a continuous index or grouped into classes, with pCR (RCB-0) and RCB-I classes having identical survival. Therefore, we evaluated the use of RCB to further discriminate between investigational and control arms. Methods: Site pathologists reported RCB for 99% of subjects in the primary efficacy analysis based on pCR (n=114/115). We compared the distribution of RCB reported as a continuous index in each treatment-subset combination to matched concurrently randomized controls using the Wilcoxon rank sum test for RCB index, and Fisher's Exact test for RCB classes (RCB-0/I vs RCB-II/III). The statistics are descriptive rather than inferential, and given the small sample size have no claim on generalizability. We modified the Bayesian model used to compute the estimated probability of success in a future, randomized, phase 3 trial of 300 subjects, if response were defined by either pCR or RCB-I (RCB0/I), or separately if it were defined by pCR alone. Results: VC+T→AC led to a significantly lower RCB index than T→AC in TNBC (p=0.0021), with a near-significant trend when those with pCR were excluded (p=0.06). There was no significant difference in RCB distributions in the other breast cancer subtypes treated. In TNBC, the odds ratio (OR) for achieving RCB-0/I in the VC+T→AC arm vs control was 8.2 (95% confidence interval (CI): 2.1–35), whereas the OR for achieving pCR was 4.56 (95% CI: 1.25–19.53). The simulations using response information from I-SPY2 to predict the probability of success for VC+T→AC for TNBC in a future phase 3 trial estimated this probability to be 0.99 if modeled using RCB-0/I as the response endpoint, and 0.90 if modeled using pCR as the response endpoint. Conclusions: Use of RCB index and classes provided additional insight into the effect of adding VC to T, appearing to magnify the improved treatment response that had been observed with pCR rates in TNBC. It will be important to test in randomized trials whether a decrease in the RCB index relative to controls, and/or increased rates of RCB-0/I class, are predictive of survival benefit in TNBC. Citation Format: Liu MC, Symmans WF, Yau C, Chen Y-Y, Rugo HS, Olopade OF, Datnow B, Chen B, Feldman M, Kallakury B, Hasteh F, Tickman R, Ritter J, Troxel M, Mhawech-Fauceglia P, Duan X, Berry D, Esserman L, DeMichele A. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-49.
Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction
Berry, Jarett D. , Brilakis, Emmanouil S. , Marso, Steven P. , Barsness, Gregory W. , Simon, DaJuanicia N., Roe, Matthew T. , Goyal, Abhinav , Kosiborod, Mikhail , Amsterdam, Ezra A. , McGuire, Darren K. , de Lemos, James A, Das, Sandeep R, Banerjee, Subhash, Roe, Matthew, Kumbhani, Dharam J, Pandey, Ambarish , Lemos, James A. de , Das, Sandeep R. , Banerjee, Subhash , Kumbhani, Dharam J. , Brilakis, Emmanouil S

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 11, 2016 | Volume: 9 | Issue: 3 | Pages: 197-205

10.1161/circoutcomes.115.002084 | PMID 27166210 Get It

Background— Current guidelines recommend surgical revascularization (coronary artery bypass graft [CABG]) over percutaneous coronary intervention (PCI) in patients with diabetes mellitus and multivessel coronary artery disease. Few data are available describing revascularization patterns among these patients in the setting of non–ST-segment–elevation myocardial infarction. Methods and Results— Using Acute Coronary Treatment and Intervention Outcomes Network Registry–Get with the Guidelines (ACTION Registry–GWTG), we compared the in-hospital use of different revascularization strategies (PCI versus CABG versus no revascularization) in diabetes mellitus patients with non–ST-segment–elevation myocardial infarction who had angiography, demonstrating multivessel coronary artery disease between July 2008 and December 2014. Factors associated with use of CABG versus PCI were identified using logistic multivariable regression analyses. A total of 29 769 patients from 539 hospitals were included in the study, of which 10 852 (36.4%) were treated with CABG, 13 760 (46.2%) were treated with PCI, and 5157 (17.3%) were treated without revascularization. The overall use of revascularization increased over the study period with an increase in the proportion undergoing PCI (45% to 48.9%; P trend =0.0002) and no change in the proportion undergoing CABG (36.1% to 34.7%; p trend =0.88). There was significant variability between participating hospitals in the use of PCI and CABG (range: 22%–100%; 0%–78%, respectively; P value <0.0001 for both). Patient-level, but not hospital-level, characteristics were statistically associated with the use of PCI versus CABG, including anatomic severity of the disease, early treatment of adenosine diphosphate receptor antagonists at presentation, older age, female sex, and history of heart failure. Conclusions— Among patients with diabetes mellitus and multivessel coronary artery disease presenting with non–ST-segment–elevation myocardial infarction, only one third undergo CABG during the index admission. Furthermore, the use of PCI, but not CABG, increased modestly over the past 6 years.
Community-Engaged Strategies to Increase Diversity of Participants in Health Education Research
Khubchandani, Jagdish , Balls‐Berry, Joyce E. , Webb, Fern J. , Balls-Berry, Joyce, Price, James H. , Balls-Berry, Joyce Joy E

Mayo Clinic

Health Promotion Practice | April 18, 2016 | Volume: 17 | Issue: 3 | Pages: 323-327

10.1177/1524839916644713 | PMID 27091602 Get It

Minorities have historically been underrepresented in health-related research. Several strategies have been recommended to increase the participation of minorities in health-related research. However, most of the recommendations and guidelines apply to research in clinical or laboratory contexts. One of the more prominent methods to enhance minority participation in health-related research that has recently come to the fore is the use of community-engaged strategies. The purpose of this article is to summarize community-engaged outreach efforts that can be translated into useable strategies for health education research teams seeking to diversify the pool of research participants. Also, we provide a succinct overview of the various components of a research endeavor that may influence minority participation in health-related research. Finally, we analyze how health education specialists and SOPHE (Society of Public Health Education) can play a leading role in helping enhance minority participation in health-related research.
The Effect of Message Framing on African American Women’s Intention to Participate in Health-Related Research
Balls‐Berry, Joyce E. , Parker, Monica W. , Halyard, Michele Y. , Albertie, Monica, Pinn, Vivian W. , Breitkopf, Carmen Radecki , Hayes, Sharonne, Halyard, Michele, Enders, Felicity , Radecki Breitkopf, Carmen, Hayes, Sharonne N. , Balls-Berry, Joyce Joy E

Mayo Clinic

Journal of Health Communication | April 14, 2016 | Volume: 21 | Issue: 5 | Pages: 527-533

10.1080/10810730.2015.1103333 | PMID 27077665 Get It

Competing Risk of Death When Comparing Tibial Implant Types in Total Knee Arthroplasty
Kremers, Hilal Maradit , Kremers, Walter K. , Lewallen, David G. , Berry, Daniel J. , Maradit Kremers, Hilal, Sierra, Rafael J. , Maradit Kremers, Hilal , Berry, Daniel J , Kremers, Walter K

Mayo Clinic

Journal of Bone and Joint Surgery | April 6, 2016 | Volume: 98 | Issue: 7 | Pages: 591-596

10.2106/jbjs.15.00488 | PMID 27053588 Get It

Background: In the presence of a competing risk of death, the Kaplan-Meier method is known to overestimate the probability of implant failure. To our knowledge, the magnitude of the competing risk of death in survivorship analyses in total knee arthroplasty has not been studied. The purpose of this study was to determine the extent of the competing risk of death in different age groups during a long-term follow-up of patients who had undergone primary total knee arthroplasty. Methods: The study population comprised 22,864 primary total knee arthroplasties at a large medical center in the United States. We compared the overall revision outcomes estimated using the Kaplan-Meier method and the cumulative incidence function over a mean follow-up of 7.8 years (range, 0.1 to 26.3 years). Results: The risk of death exceeded the risk of revision by a factor of 4 at twelve years following the surgical procedure. The Kaplan-Meier method overestimated the risk of revision by 3% at five years, 14% at ten years, 32% at fifteen years, and 57% at twenty years. At ten years after the surgical procedure, the risk of death exceeded the risk of revision by a factor of 15 in the all-polyethylene group and by a factor of 3.5 in the metal modular group. The Kaplan-Meier method overestimated the ten-year risk of revision by 18% in the all-polyethylene group and by 11% in the metal modular group. After accounting for the higher competing risk of death in the all-polyethylene group, the cumulative incidence of revision in the metal modular group was about 2.5 to three times higher than that in the all-polyethylene group at ten years. Conclusions: Although the Kaplan-Meier and cumulative incidence methods yielded different implant survival estimates beyond ten years (Kaplan-Meier overestimates implant failure), the size of the bias was small at earlier time points. The extent of overestimation depends on the duration of follow-up and the magnitude of the competing risk of death. Clinical Relevance: This study examines the clinical relevance of the competing risk of death in total knee arthroplasty.
Epidemiology of periprosthetic femoral fractures in 5417 revision total hip arthroplasties
Watts, Chad D. , Lewallen, David G. , Berry, Daniel J. , Abdel, Matthew P. , Houdek, Matthew T. , Berry, Daniel J , Pagnano, Mark W

Mayo Clinic

The Bone & Joint Journal | April 1, 2016 | Volume: 98-B | Issue: 4 | Pages: 468-474

10.1302/0301-620x.98b4.37203 | PMID 27037428 Get It

Aims The goals of this study were to define the risk factors, characteristics, and chronology of fractures in 5417 revision total hip arthroplasties (THAs). Patients and Methods From our hospital’s prospectively collected database we identified all patients who had undergone a revision THA between 1969 and 2011 which involved the femoral stem. The patients’ medical records and radiographs were examined and the relevant data extracted. Post-operative periprosthetic fractures were classified using the Vancouver system. A total of 5417 revision THAs were identified. Results There were 668 intra-operative fractures, giving an incidence of 12%. Fractures were three times more common with uncemented stems (19%) than with cemented stems (6%) (p < 0.001). The incidence of intra-operative femoral fracture varied by uncemented stem type: fully-coated (20%); proximally-coated (19%); modular fluted tapered (16%) (p < 0.05). Most fractures occurred during the insertion of the femoral component (35%). One-third involved the diaphysis and 26% were of the calcar: 69% were undisplaced. There were 281 post-operative fractures of the femur (20-year probability = 11%). There was no difference in risk for cemented and uncemented stems. Post-operative fractures were more common in men < 70 years (p = 0.02). Periprosthetic fractures occurred earlier after uncemented revision of the femoral component, but later after a cemented revision. The most common fracture type was a Vancouver B 1 (31%). Of all post-operative fractures, 24% underwent open reduction and internal fixation and 15% revision arthroplasty. Conclusion In revision THA, intra-operative fractures occurred three times more often with an uncemented stem. Many were undisplaced diaphyseal fractures treated with cerclage fixation. While the risk of post-operative fracture is similar between uncemented and cemented components, they occur at notably different times depending on the type of stem fixation. Take home message: In revision THA, intra-operative periprosthetic femoral fractures occur three times more often with uncemented stems. Many are non-displaced diaphyseal fractures treated with cerclage fixation. While postoperative fracture risks are equivalent between uncemented and cemented components, they occur at notably different time periods based on stem fixation type. Cite this article: Bone Joint J 2016;98-B:468–74.
Epidemiology of periprosthetic fracture of the femur in 32 644 primary total hip arthroplasties
Watts, Chad D. , Lewallen, David G. , Abdel, Matthew P. , Houdek, Matthew T. , Berry, Daniel J. , Pagnano, Mark W

Mayo Clinic

The Bone & Joint Journal | April 1, 2016 | Volume: 98-B | Issue: 4 | Pages: 461-467

10.1302/0301-620x.98b4.37201 | PMID 27037427 Get It

Aim and Methods The goals of this study were to define the risk factors, nature, chronology, and treatment strategies adopted for periprosthetic femoral fractures in 32 644 primary total hip arthroplasties (THAs). Results There were 564 intra-operative fractures (1.7%); 529 during uncemented stem placement (3.0%) and 35 during cemented stem placement (0.23%). Intra-operative fractures were more common in females and patients over 65 years (p < 0.001). The majority occurred during placement of the femoral component (60%), and involved the calcar (69%). There were 557 post-operative fractures (20-year probability: 3.5%; 95% confidence interval (CI) 3.2 to 3.9); 335 fractures after placement of an uncemented stem (20-year probability: 7.7%; 95% CI 6.2 to 9.1) and 222 after placement of a cemented stem (20-year probability: 2.1%; 95% CI 1.8 to 2.5). The probability of a post-operative fracture within 30 days after an uncemented stem was ten times higher than a cemented stem. The most common post-operative fracture type was a Vancouver A G (32%; n = 135), with 67% occurring after a fall. In all, 36% (n = 152) were treated with revision arthroplasty. Conclusion In summary, intra-operative fractures occur 14 times more often with uncemented stems. Female patients over 65 years of age are at highest risk. Post-operative fractures are also most common with uncemented stems, but are independent of age or gender. Cumulative risk of post-operative periprosthetic femur fracture was 3.5% at 20 years. Take home message: Intra-operative fractures occur 14 times more often with uncemented stems, particularly with female patients over 65 years of age, while post-operative fracture risk is independent of age or gender, but still increased with uncemented stems. Cite this article: Bone Joint J 2016;98-B:461–7.
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907
Lichtman, Stuart M. , Cirrincione, Constance, Hurria, Arti , Jatoi, Aminah , Theodoulou, Maria, Wolff, Antonio C. , Morganstern, Daniel, Magrinat, Gustav , Cohen, Harvey Jay, Muss, Hyman B. , Cirrincione, Constance T, Gralow, Julie, Morganstern, Daniel E, Gralow, Julie R. , Wolff, Antonio C , Lichtman, Stuart M

Mayo Clinic

Journal of Clinical Oncology | January 12, 2016 | Volume: 34 | Issue: 7 | Pages: 699-705

10.1200/jco.2015.62.6341 | PMID 26755510 Get It

Purpose CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the treatment of patients age ≥ 65 with early-stage breast cancer. The treatment allowed dosing adjustments of methotrexate and capecitabine for pretreatment renal function. The purpose of the current analysis was to assess the relationship between pretreatment renal function and five end points: toxicity, dose modification, therapy completion, relapse-free survival, and overall survival. Methods Pretreatment renal function was defined as creatinine clearance (CrCl) using the Cockcroft-Gault equation. Multivariable logistic and proportional hazards regression were used to model separately for each regimen the relationship between CrCl and the first three binary end points and the last two time-to-event end points, respectively, after adjusting for variables of prognostic importance. Results Six hundred nineteen assessable patients were analyzed. The incidence of stage III (moderate) or stage IV (severe) renal dysfunction was 72%, 64%, and 75% for treatment with cyclophosphamide/methotrexate/fluorouracil, AC, and capecitabine, respectively. There was no relationship for any regimen between pretreatment renal function and the five end points. For AC, as CrCl increased, the odds of nonhematologic toxicity decreased (P = .008), whereas for capecitabine, as CrCl increased, the odds of experiencing toxicity of any type also increased (P = .035). Patients with renal insufficiency who received dose modifications were not at increased risk for complications compared with those who did not have renal insufficiency and received a full dose. Conclusion Excluding from clinical trials patients with renal insufficiency but good performance status on the basis of concern of excessive hematologic toxicity or poor outcomes may not be justified with appropriate dosing modifications. Results should be considered in the design of clinical trials for older patients.
ALS biomarkers for therapy development: State of the field and future directions
Benatar, Michael , Jeromin, Andreas, Rutkove, Seward B. , Atassi, Nazem , Bruijn, Lucie, Boylan, Kevin, Boylan, Khrista , Berry, James D.

Mayo Clinic

Muscle & Nerve | November 17, 2015 | Volume: 53 | Issue: 2 | Pages: 169-182

10.1002/mus.24979 | PMID 26574709 Get It